CAM
ZNTL icon

Cormorant Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Cormorant Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-700,000
Closed -$14M – 56
2023
Q3 		$14M Sell
700,000
-395,000
-36% -$10M 0.82% 30
2023
Q2 		$30.9M Buy
+1,095,000
New +$26.3M 1.73% 13

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Cormorant Asset Management's ZNTL Position: Q4 2023 in Review

Cormorant Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2023, closing a stake of 700,000 shares — an estimated $14M sold.

Cormorant Asset Management first reported a position in ZNTL in Q2 2023 and held it in 2 quarters. The position peaked at $30.9M in Q2 2023. 120 funds tracked by Wall St. Rank hold ZNTL as of Q4 2023.

  • Cormorant Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cormorant Asset Management sold 700,000 Zentalis Pharmaceuticals shares in Q4 2023, an estimated $14M.
  • Cormorant Asset Management first reported a position in Zentalis Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Cormorant Asset Management's Zentalis Pharmaceuticals position peaked at $30.9M in Q2 2023.
  • 120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2023.

Based on Cormorant Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.